Enterisol Ileitis lyophilisate and solvent for oral suspension for pigs

País: Irlanda

Língua: inglês

Origem: HPRA (Health Products Regulatory Authority)

Ingredientes ativos:

Attenuated live bacteria lawsonia intracellularis (ms b3903)

Disponível em:

Boehringer Ingelheim Ltd

Código ATC:

QI09AE04

DCI (Denominação Comum Internacional):

Attenuated live bacteria lawsonia intracellularis (ms b3903)

Dosagem:

1x10^4.9 to 1x10^6.1 tissue culture infective dose 50/dose

Forma farmacêutica:

Lyophilisate + solvent for suspension

Tipo de prescrição:

POM: Prescription Only Medicine as defined in relevant national legislation

Grupo terapêutico:

Pigs

Área terapêutica:

lawsonia

Indicações terapêuticas:

Immunological - Live Vaccine

Status de autorização:

Authorised

Data de autorização:

2005-07-07

Características técnicas

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Enterisol Ileitis lyophilisate and solvent for oral suspension for
pigs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose (2 ml) contains:
Lyophilisate:
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Lyophilisate and solvent for oral suspension.
Lyophilisate: light yellow to gold.
Solvent: clear, colourless solution.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Pigs
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For active immunisation of weaned pigs from three weeks of age and
older to reduce the intestinal lesions caused by
_Lawsonia intracellularis_ infection and to reduce growth variability
and loss of weight gain associated with the disease.
Under field conditions, the difference in average daily weight gain
was seen to be up to 30 g/day when vaccinated pigs
were compared to unvaccinated pigs.
Onset of protection occurs as early as 3 weeks post vaccination and
lasts for at least 17 weeks.
4.3 CONTRAINDICATIONS
None.
ACTIVE SUBSTANCE:
QUANTITY:
Live attenuated_ Lawsonia intracellularis (MS B3903)_: At least:
1 x 10
TCID
*
Maximum:
1 x 10
TCID
*
* Tissue Culture Infective Dose 50%
4.9
50
6.1
50
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_3_
_/_
_1_
_2_
_/_
_2_
_0_
_1_
_6_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_3_
_4_
_3_
_6_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
The vaccine has not been tested in breeding boa